Rocket Pharmaceuticals, INC 8-K filings

Rocket Pharmaceuticals announced strong Q2 2026 results, highlighted by the FDA approval of KRESLADI, a $180 million capital infusion from its sale, and positive initial safety data for its Danon disease gene therapy.

Rocket Pharmaceuticals announced a positive clinical safety update for its RP-A501 gene therapy in Danon disease, with initial patients showing good tolerance and no major adverse events.

Rocket Pharmaceuticals, Inc. has announced the resignation of its VP of Finance, Senior Controller, Treasurer, and Principal Accounting Officer, John Militello, effective July 7, 2026, and the appointment of Joseph Manhede as the new Principal Accounting Officer, effective July 8, 2026.

Rocket Pharmaceuticals has completed the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million in non-dilutive capital.

Rocket Pharmaceuticals held its 2026 Annual Meeting of Stockholders, with a strong majority approving the election of directors, ratification of its accounting firm, executive compensation, and a stock option exchange program.

Rocket Pharmaceuticals announced first-quarter 2026 financial results, highlighting progress in clinical trials and the monetization of a Priority Review Voucher, extending their operational runway into Q2 2028.

Rocket Pharmaceuticals announced the sale of its Rare Pediatric Disease Priority Review Voucher for $180 million, significantly extending its cash runway into Q2 2028.

Rocket Pharmaceuticals announced FDA accelerated approval of KRESLADI, its gene therapy for severe pediatric LAD-I, and received a Rare Pediatric Disease Priority Review Voucher.

Rocket Pharmaceuticals announced its fourth quarter and full year 2025 financial results, highlighting progress in its gene therapy pipeline and an extended cash runway.

Rocket Pharmaceuticals reported Q3 2025 financial results, highlighted the lifting of the clinical hold for its pivotal Danon disease trial, and confirmed a March 2026 PDUFA date for KRESLADI.

Rocket Pharmaceuticals announced the FDA accepted its Biologics License Application resubmission for KRESLADI, a gene therapy for severe LAD-I, setting a PDUFA date of March 28, 2026.

Pedro Granadillo has resigned from Rocket Pharmaceuticals' Board of Directors, effective September 30, 2025, with no reported disagreements.

Rocket Pharmaceuticals has voluntarily withdrawn its Biologics License Application for investigational gene therapy RP-L102 for Fanconi Anemia, citing strategic prioritization.

Rocket Pharmaceuticals, Inc. announced the appointment of Dr. Peter Fong, President of RTW Investments LP, to its Board of Directors, following the resignation of Dr. Gotham Makker.

Rocket Pharmaceuticals announced the departure of Dr. Kinnari Patel, who will transition to a consulting role while joining RTW Investments LP as a venture partner.

Rocket Pharmaceuticals, Inc. announced the resignation of its Chief Financial Officer, Aaron Ondrey, and the appointment of Martin Wilson as interim Principal Financial Officer.

Rocket Pharmaceuticals announced the FDA has lifted the clinical hold on its pivotal Phase 2 trial for RP-A501, a gene therapy for Danon disease, allowing the study to resume with a recalibrated dose and revised immunomodulatory regimen.

Rocket Pharmaceuticals reports Q2 2025 financial results, announces a strategic pivot to cardiovascular gene therapies, and implements a significant workforce reduction following a clinical hold on its lead Danon disease program.

Rocket Pharmaceuticals announced a strategic corporate reorganization and pipeline prioritization to focus on its AAV cardiovascular programs, reduce headcount by 30%, and extend its operational runway into Q2 2027.

Rocket Pharmaceuticals, Inc. is implementing a strategic corporate reorganization, including a 30% workforce reduction, to maximize near-term value and extend its operational runway into Q2 2027.

Rocket Pharmaceuticals announced that its investigational gene therapy, RP-A601, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for PKP2-arrhythmogenic cardiomyopathy, signaling expedited development and review.

Rocket Pharmaceuticals, Inc. announced the appointment of Christopher Stevens, a seasoned executive with extensive experience in gene therapy manufacturing and supply chain, as its new Chief Operating Officer, effective July 7, 2025.

Rocket Pharmaceuticals, Inc. announced that its stockholders approved all three proposals at the 2025 Annual Meeting, including the election of ten directors, the ratification of EisnerAmper LLP as independent auditors, and the advisory vote on executive compensation.

Rocket Pharmaceuticals announced its Phase 2 clinical trial for RP-A501 in Danon disease was placed on clinical hold by the FDA following a serious adverse event and subsequent patient death, leading to an indefinite delay in trial completion.

Rocket Pharmaceuticals reports encouraging initial data from its Phase 1 clinical trial of RP-A601 for plakophilin-2 related arrhythmogenic cardiomyopathy (PKP2-ACM), showing a favorable safety profile and potential clinical benefits.

Rocket Pharmaceuticals announces its Q1 2025 financial results, highlighting progress in its gene therapy programs and an expected operational runway into Q4 2026.

R. Keith Woods will not seek re-election to Rocket Pharmaceuticals' board after accepting a Chief Operating Officer position at another biopharmaceutical company.

Rocket Pharmaceuticals appoints Sarbani Chaudhuri as Chief Commercial & Medical Affairs Officer, effective April 7, 2025, with a compensation package including a $525,000 base salary, bonus potential, and equity grants.

Rocket Pharmaceuticals announces financial results for Q4 and full year 2024, highlighting advancements in its gene therapy pipeline and a cash runway into Q3 2026.

Rocket Pharmaceuticals announces the resignation of Naveen Yalamanchi from its Board of Directors and the appointment of Piratip Pratumsuwan, effective January 27, 2025.